drugset / Trial / NCT02474667
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
Phase 3
Unknown
253 enrolled
Angion Biomedica Corp
CTI Clinical Trial and Consulting Services · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft.
Timeline
- Start
- 2016-03
- Primary completion
- 2021-09
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TEREVALEFIM | Small molecule | — | Intravenous |
Indications
No indication recorded.